Forest to file hypertension combo NDA on Phase III success
This article was originally published in Scrip
Forest Laboratories said it will file a new drug application (NDA) with the US FDA during the first quarter of 2014 for its fixed-dose combination (FDC) of the blood pressure-lowering agents Bystolic (nebivolol) and Diovan (valsartan) based on the results of a Phase III study.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.